Angina Pectoris Treatment Market Outlook, Key Financials, Segmental Revenue and Geographical Revenue till 2026

Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to an uncomfortable pressure, fullness, squeezing or pain in the center of the chest.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1158

The factors that trigger stable angina pectoris include emotional stress, exposure to very hot or cold temperature, heavy meals or smoking. Angina pectoris can be diagnosed by an electrocardiogram and angiography and could be treated by medication, change in life style, and surgery. A minimal invasive procedure known as angioplasty is also used to treat the angina pectoris. The pain or discomfort caused by angina pectoris is relieved with rest and nitroglycerin. Nitroglycerin relaxes the coronary arteries and other blood vessels by increasing the blood flow to the heart vessels.

Angina Pectoris Treatment Market Taxonomy

By Drug Class:

• Beta Blockers
• Calcium Channel Blockers
• Nitrates
• Angiotensin-converting Enzyme Inhibitors
• Others

By Indication:

• Stable Angina
• Unstable Angina

Quick Buy – Angina Pectoris Treatment Market Research Report: https://bit.ly/3bQvGnR

New product launches and strong pipeline are expected to fuel growth of the angina pectoris treatment market

In June 2016, Espero announced about receiving approval from the U.S. Food and Drug Administration (FDA) for GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. In February 2016, AstraZeneca sold the rights of its two medicines Plendil and Imdur for US$ 500Mn. China Medical System Holdings (CMS) agreed to pay AstraZeneca US$ 310 Mn for commercialization rights of Plendil (felodipine) in China. Plendil is a calcium antagonist indicated for both hypertension and the prophylaxis of the chronic stable angina pectoris. Whereas, Imdur is an oral extended-release formulation of isosorbide mononitrate indicated for the prevention of angina pectoris due to coronary artery disease.

Furthermore, Amgen offers Corlanor (Ivabradine) for the treatment of angina pectoris in its pipeline (phase 3), which was launched in 2015 at Annual Scientific Session. In November 2016, Allergan also presented new data on BYSTOLIC (nebivolol) for the treatment of hypertension to lower blood pressure at the Annual American Heart Association Meeting in New Orleans. Whereas, Perrigo announced FDA approval of its abbreviated new drug application (ANDA) for Nitroglycerin Lingual Spray in 2013, the generic version of Shionogi’s Nitrolingual Pumpspray is indicated for acute attacks and prophylaxis of angina pectoris.

Strategic activities by market players to increase their market share

Angina pectoris treatment market is driven by factors such as increasing number of collaborations, product launches and approvals, and mergers and acquisitions. For instance, Recordati acquired AstraZeneca blood pressure brand Metoprolol, in 2017, which is a beta-blocker used mainly for the conditions, such as angina pectoris, hypertension, and heart disorders. Furthermore, Pharmaceutical manufacturer Lupin received approval from the U.S. FDA in 2017 to launch the generic version of the U.S WorldMeds’ nadolol drug indicated for the patients with angina pectoris and for the treatment of hypertension. Moreover, patent expiry of Ranolazine drug from Gilead Sciences, Inc. in 2019 is expected to offer growth opportunities for generic drug manufacturers in the global angina pectoris treatment market.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/angina-pectoris-treatment-market-1158

The key players operating in the global market of angina pectoris treatment market include Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Allergan plc, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Sanofi SA.

Table of Content

Global Angina Pectoris Treatment Market Research Report
Section 1: Global Angina Pectoris Treatment Industry Overview
Section 2: Global Economic Impact on Angina Pectoris Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Angina Pectoris Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Angina Pectoris Treatment Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837